Nervelight
Latest Information Update: 23 Sep 2024
Price :
$50 *
At a glance
- Originator Manzanita Pharmaceuticals
- Class Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Sep 2024 Manzanita Pharmaceuticals has patents pending for Nervelight™, prior to September 2024 (Manzanita Pharmaceuticals pipeline, September 2024)
- 09 Sep 2024 Preclinical trials in Cancer (Diagnosis) in USA (Topical), prior to September 2024 (Manzanita Pharmaceuticals pipeline, September 2024)
- 02 Feb 2020 Pharmacodynamics data from a preclinical trial in Cnacer released by Manzanita Pharmaceuticals